$423.56 Million in Sales Expected for Chemed Co. (CHE) This Quarter
Equities research analysts forecast that Chemed Co. (NYSE:CHE) will announce sales of $423.56 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Chemed’s earnings, with the highest sales estimate coming in at $425.40 million and the lowest estimate coming in at $421.72 million. Chemed reported sales of $403.48 million during the same quarter last year, which would indicate a positive year over year growth rate of 5%. The business is scheduled to issue its next quarterly earnings results after the market closes on Wednesday, February 14th.
On average, analysts expect that Chemed will report full-year sales of $423.56 million for the current fiscal year. For the next financial year, analysts anticipate that the firm will post sales of $1.73 billion per share, with estimates ranging from $1.69 billion to $1.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Chemed.
Chemed (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to the consensus estimate of $414.34 million. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.73 earnings per share.
In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $250.00, for a total transaction of $250,000.00. Following the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Naomi C. Dallob sold 750 shares of the stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $222.09, for a total transaction of $166,567.50. Following the transaction, the vice president now directly owns 9,097 shares in the company, valued at approximately $2,020,352.73. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,679 shares of company stock worth $10,628,959. 4.90% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of CHE. Acrospire Investment Management LLC acquired a new stake in shares of Chemed in the second quarter worth $120,000. IFP Advisors Inc increased its position in shares of Chemed by 1,504.5% in the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Chemed by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares in the last quarter. MCF Advisors LLC acquired a new stake in shares of Chemed in the third quarter worth $152,000. Finally, Magnetar Financial LLC acquired a new stake in shares of Chemed in the third quarter worth $207,000. 97.71% of the stock is currently owned by institutional investors.
Chemed (CHE) opened at $263.97 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The stock has a market cap of $4,176.87, a P/E ratio of 58.66, a P/E/G ratio of 2.94 and a beta of 1.16. Chemed has a one year low of $163.50 and a one year high of $266.31.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.